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Abstract 
Increased glutamine metabolism (glutaminolysis) is a hallmark of cancer and is recognised as 
a key metabolic change in cancer cells. As a heterogeneous disease with different morpholog-
ical and molecular subtypes and response to therapy, breast cancer cells are known to rewire 
glutamine metabolism to support survival and proliferation. Glutaminase isoenzymes (GLS 
and GLS2) are key enzymes for glutamine metabolism. Interestingly, GLS and GLS2 display 
contrasting functions in tumourigenesis. In this review, we explore the role of glutaminase in 
cancer, primarily focussing on breast cancer, address the role played by oncogenes and tu-
mour suppressor genes in regulating glutaminase, and discuss current therapeutic approaches 
in targeting glutaminase. 
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Introduction  
An established hallmark of cancer is undergoing metabolic reprogramming to maintain high 
demand for energy needed to sustain proliferation and survival [1]. Cancer cells alter their 
glucose and glutamine metabolism to acquire sufficient energy and cellular building blocks 
needed to support this unremitting growth. Some consume more glucose showing aerobic 
glycolysis or the ‘Warburg effect’, where glucose is converted mainly to lactic acid instead of 
engaging in the mitochondrial oxidative phosphorylation to allow proper respiration [2-4]. 
Other cancer cell types fail to grow or proliferate in the absence of glutamine and display 
‘glutamine addiction’ [5], which helps the cells to sustain high proliferative rates under condi-
tions of hypoxia and glucose depletion [6-8] (Figure 1).  
The intracellular processing of glutamine begins with its catalysis by glutaminase. In this re-
view we discuss the role, regulation and relevance of glutaminase and its isozymes and splice 
variants in cancer particularly focussing on breast cancer (BC). We further highlight the op-
portunities that exist in utilising glutaminase as a therapeutic target. 
Glutamine metabolism and addiction in cancer 
Glutamine metabolism plays an important role in normal cell metabolism and generating en-
ergy for the rapidly proliferating cells and tissues. As the most abundant amino acid in blood 
circulation, glutamine serves directly or indirectly, via its metabolic products glutamate and 
alpha ketoglutarate, as carbon and nitrogen sources needed for the biosynthesis of nucleic 
acids, fatty acids and proteins. Some cancers can become highly dependent on glutamine [1, 
4, 9] such that the demand for glutamine outpaces supply. Additionally, some tumour cells in 
vitro are unable to survive in the absence of an exogenous supply of glutamine [8, 10]. Con-
sequently cells develop a metabolic strategy to provide an alternative source of carbon other 
than glucose to derive carbon necessary to fuel the TCA cycle [11]. Recently, it has been 
shown that glutamine can enhance cancer progression independent of its metabolic role as it 
can act as a signalling agent to activate the transcription factor STAT3 which is required to 
mediate the proliferative effects of glutamine on cancer cells [12]. Furthermore, glutamine 
can indirectly activate other signalling pathways, such as the mammalian target of rapamycin 
complex 1 (mTORC1), a critical kinase that regulates cell growth and proliferation, as gluta-
mine derived α-ketoglutarate is required for GTP loading of RagB and subsequent activation 
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of mTORC1[13]. Additionally, glutamine efflux through SLC7A5 is coupled by leucine up-
take. The latter is known as a potent activator of mTORC1 [14]. 
The maintenance of redox homeostasis in cancer is important because the highly proliferating 
cells that encounter increased reactive oxygen species (ROS) production due to enhanced 
glutamine metabolism need a defence mechanism to avoid apoptosis [15]. Glutamine has a 
role in maintaining the redox balance through different mechanisms. Metabolites produced 
during the TCA cycle, serve as precursors for the reducing agent, Nicotinamide Adenine 
Dinucleotide Phosphate (NADPH). Furthermore, exchange of intracellular glutamate through 
the transporter SLC7A11 mediates the Cysteine uptake. This amino acid is then reduced to 
cysteine, the rate-limiting product for glutathione (GSH) biosynthesis [16]. Both, NADPH 
and GSH, act as a key regulator of cellular redox status [11, 15].   
Glutaminase isoforms 
In humans, glutaminase exists as two isoforms; kidney-type (GLS) and liver-type (GLS2), 
which not only differ in kinetic properties but also in protein structure and tissue distribution 
[17]. GLS and GLS2 are encoded by the GLS and GLS2 genes respectively [18] and both can 
undergo alternative splicing to produce several variants (Figure 2). GLS (KGA; long tran-
script), GLS C (GAC; short transcript) and GAM are encoded by the GLS gene. However, 
GAM is significantly shorter than KGA or GAC and exhibits no measurable catalytic activity 
whereas GAC has greater catalytic activity and is frequently upregulated in cancer cells [19, 
20]. GLS2 (LGA; shorter transcript) and GAB (long transcript isoform) splice variants en-
coded by the GLS2 gene also exist [17, 18, 21].  
Role of Glutaminase in Cancer 
In cancer, the two GLS isozymes have opposing roles in tumourigenesis. GLS correlates with 
tumour growth rate and malignancy and is regulated by the oncogene c-MYC, whereas GLS2 
tends to have tumour suppressive features and is regulated by p53 [17, 22-24]. Upregulation 
of GLS is observed in cancers including breast, liver, colorectal, brain, cervix, lung and 
melanoma [20, 25]. Rapidly growing malignant cells have elevated mRNA levels and en-
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hanced GLS protein expression [24, 26-28] and GLS enzymatic activity correlates with poor 
disease outcome in liver, lung, colorectal, breast and brain tumours [24, 25, 29-32]. It is how-
ever the GAC variant which is a key enzyme for cancer cell growth [20, 28, 33, 34]. 
It appears that post-translational phosphorylation of GAC at specific regions of the enzyme 
by different signalling pathways can alter GLS activity [28, 33, 35]. Phosphorylation of GAC 
at Ser314 by oncogenic proteins Rho-C regulated PKCε kinase is responsible for elevated 
GAC activity [35]. In contrast, serine 95 phosphorylation at the GLS N-terminal region leads 
to decreased GLS activity [33].  
The expression of GLS2 variants are markedly increased in tumour cells that are more differ-
entiated and is associated with a significantly prolonged survival time [24, 25, 36, 37]. GLS2 
negatively regulates the activity of PI3K/AKT signalling [38] and Rac1 by mediating p53 
function in HCC resulting in the inhibition of migration, invasion and metastasis of cancer 
cells [25, 27]. 
Glutamine Dependency in Breast Cancer 
The need for glutamine varies according to different BC molecular subtypes [34-35, 41] 
where only some require an exogenous supply of glutamine and demonstrate glutamine de-
pendence [38]. For example, triple-negative BC (TNBC) and HER2+ cell lines are highly 
glutamine dependent whereas luminal tumours have variable glutamine dependence [32, 39, 
40]. Luminal A tumours are primarily glutamine independent as they exhibit only moderate 
effects on growth and viability in a glutamine-deprived environment whereas Luminal B cells 
show much higher glutamine metabolic activity [41]. 
Glutaminase in Breast Cancer 
When interrogating Breast Cancer Gene-Expression Miner v4.3 (http://bcgenex.centre-
gauducheau.fr), GLS and GLS2 mRNA expression are negatively correlated (Figure 3). GLS 
is associated with high grade (p=0.006) whereas GLS2 is associated with low grade 
(p<0.0001) tumours . In a relatively small study of breast tumours, high GLS protein was as-
sociated with high tumour grade and high grade metastatic BC but not tumour size, or nodal 
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stage [42][20]. In terms of BC patient outcome, GLS mRNA expression predicts poor patient 
survival (Figure 4a) and high GLS2 mRNA predicts a better survival (Figure 4b). 
In biological subtypes, GLS mRNA and/or protein expression is higher in basal-like/TNBC 
and HER2+ tumours and associated with poor-disease free survival in patients with positive 
lymph node metastasis [40]. Luminal B tumours have higher expression of GLS protein 
compared with Luminal A tumours and is predictive of poor patient outcome [30, 42-45]
(Figure 3). 
In contrast, GLS2 mRNA is significantly higher in luminal A tumours compared with luminal 
B, HER2+ and TNBC (Figure 3). However, there is very little published information on 
GLS2 protein expression in cancer, including BC. Interestingly, patients with tumours ex-
pressing GLS but not GLS2 confers a worse survival (Figure 4c) which is only observed in 
Luminal B tumours (Figure 4d).  
Glutaminase Regulation in Cancer - Role of Oncogenes and Tumour Suppressor Genes 
c-Myc plays a key role in the induction of glutamine dependence as it can enhance glutamine 
influx and metabolism. There is evidence that GLS, both splice variants KGA and GAC, are 
positively regulated by c-myc and are strongly expressed in c-Myc induced tumours [26, 34, 
46, 47]. Tumours exhibiting overexpression of c-Myc with elevated GLS expression, together 
with a high influx of glutamine into the cells, consequently become glutamine addicted [10, 
48]. 
c-Myc transcription stimulates GLS expression through different mechanisms [34, 48-50]. 
GLS is partly upregulated by microRNAs (miRNAs) where its translation is repressed by 
miR-23a/b through the mTORC1 pathway. Moreover, cancer cells that are dependent on Rho 
GTPase signaling via NF-κB activity for progression of malignancy have activated GAC and 
consequently elevated level of GLS activity [28, 51, 52].  
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Conversely, GLS2 is induced by p53, in response to oxidative stress, to engage antioxidant 
responses in order to decrease ROS levels and participate in DNA damage repair processes 
[53]. Hu et al, 2010 showed that GLS2 is a p53 target gene containing p53 DNA-binding 
elements in the promoter region and that in turn GLS2 mediates p53 function in the regula-
tion of energy metabolism and antioxidant defence in cells [22, 54]. 
 
The difference in the catalytic activity of GLS and GLS2 could be due to the underlying regu-
latory mechanisms. The deamination of glutamate by GLS results in the release of ammonia 
which is essential to support cell survival processes through providing alpha-ketoglutarate 
and intermediates for biosynthesis.  However, glutamate produced from GLS2 activity sup-
ports the antioxidant machinery/mechanism (glutathione) in the cell cycle. 
Potential Therapeutic Uses 
Since glutaminase is critical for tumour growth and predominantly upregulated in highly pro-
liferating breast tumours and a key enzyme in the first step of glutamine catabolism, it has the 
potential for acting as a target for therapy. 
Glutaminase Inhibitors 
6-diazo-5-oxo-L-norleucine (L-DON) GLS inhibitor is the earliest inhibitor of both GLS and 
GLS2 to be used in preclinical models. As a result of its non-selectivity and undesirable ef-
fects due to having similar structure to glutamine and having reactive chemical compounds, 
other compounds were developed [55]. Recently, two small molecules that inhibit both GLS 
and GLS2 have been determined: Bis-2-(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl) ethyl 
sulfide (BPTES) and dibenzophenanthridine-968. In vitro and mouse model xenograft studies 
show that BPTES significantly inhibits GLS over GLS2 [28, 55, 56] in various cancer types. 
Whereas the 968-class of inhibitors inhibit GLS and GLS2 with similar potency [17, 57]. 
On the other hand, BPTES is a potent GLS inhibitor with minimal toxicity. The inhibitor does 
not exhibit structural similarities to glutamate or glutamine. However, it forms an inactive 
tetramer complex site where it interacts with GLS and not at the site where glutamine is 
catalysed. Thus there is no competition in the inhibition of GLS with the molecule [58]. 
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BPTES inhibits GLS activity in glioma cells where glutamate and α-KG levels are decreased 
leading to a decrease in subsequent TCA cycle intermediates and its downstream products 
and slowed tumour growth [56]. BPTES also suppresses cell proliferation in HER2+ BC cells 
associated with increased GLS activity [59]. Although BPTES selectively inhibits GLS over 
GLS2 [53], it is described to have limitation in pharmacological application due to its poor 
metabolic stability, low solubility and moderate potency [57]. Like BPTES, Compound 968 is 
an allosteric inhibitor of GLS and inhibits the activity of KGA and GAC [60]. In vitro and 
mouse Xenograft model studies have shown anti-tumour activity of the compound in lym-
phoma, BC, ovarian and glioblastoma cells [24, 28, 61]. 
Very recently, evidence regarding inhibition of glutaminase as a therapeutic approach in 
treatment of cancer has resulted in the development of a BPTES derivative, 2-(pyridin-2-yl)-
N-(5-(4-(6-(2-(3-(trifluoromethoxy) phenyl) acetamido) pyridazin-3-yl) butyl)-1, 3, 4-thiadi-
azol-2-yl) acetamide (CB-839) [8]. Like BPTES, CB-839 is a member of the 
benzo[a]phenanthridinone family containing a pryridazine ring. The small molecule is a GLS 
inhibitor that regulates the enzymatic activity of KGA and predominantly the GAC splice 
variant isoenzyme [28, 40] by targeting the allosteric site of GLS. The inhibitor works by 
binding to and stabilising an inactive tetrameric state of the enzyme, rather than by competi-
tion with glutamine for binding to the active site where glutamine is hydrolysed [53, 56]. CB-
839 is a more potent compound in terms of inhibition of GLS compared with BPTES [28, 55, 
58]. In addition, CB-839 has an inhibitory concentration of 30- and 50-fold lower than 
BPTES [62]. 
Pre-clinical models demonstrate that CB-839 displays significant growth inhibition in certain 
subtypes of BC. Gross et al, 2014 demonstrated that TNBC are sensitive to CB-839 com-
pared to luminal A/ER+ cells (MCF-7) mainly because of their high glutamine dependence 
and enhanced glutamine utilisation. Treatment of TNBC with CB-839 lowered levels of 
glutamate suggesting blockage of glutamine metabolism by inhibiting GLS [8]. Consistent 
with the findings, CB-839 inhibits signaling pathways in transformed cells via Rho GTPases 
which are linked to the activation of GLS hence, inhibiting the enzyme invasive activity. The 
treatment with CB-839 resulted in reduced TNBC growth in mice models injected with tu-
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mour cells by half. However, the inhibitory effect of CB-839 on the growth of the other 
highly proliferative BC subtypes, i.e. luminal B and HER2+, has yet to be comprehensively 
confirmed. 
FUTURE PERSPECTIVES 
The GLS inhibitor CB-839 has already shown promising results in several solid cancers in-
cluding TNBC and therefore has a strong therapeutic potential particularly in those exhibiting 
high glutamine dependency [63]. Phase I and II clinical trials currently being conducted are 
summarised in Table 2. A further GLS allosteric inhibitor, UPGL00004, shows similar poten-
cy in TNBC with additional growth inhibition in combination with the anti-vascular endothe-
lial growth factor antibody bevacizumab [64].  
Whilst TNBC have high dependence on glutamine, it certainly appears that glutaminase, par-
ticularly GLS but potentially GLS2, also plays an important role in the aggressive subclass of 
luminal BC. Therefore it is essential to elucidate the role of glutaminolysis in luminal B BC 
growth and progression and whether GLS offers a potential new therapeutic option for these 
BC patients whom have an uncertain prognosis due to relapse and/or development of resis-
tance to current therapies. 
 
Indeed, a most recent finding has provided some initial evidence that a luminal B-like patient 
xenograft is sensitive to CB-839 [65] demonstrating its potential use against other BC sub-
types than TNBC alone. GLS inhibition in the luminal B xenograft model resulted in inhibi-
tion of the downstream metabolites proline and alanine indicating that its sensitivity is per-
haps linked to it not being able to adapt to hypoxic environment through activation of proline 
mechanisms. It certainly suggests that BC subtypes might possibly be dependent on different 
glutamine metabolic characteristics. 
Conclusion 
Glutaminase plays a key role in various tumours including BC, which exhibit deregulated 
glutaminolysis because of overexpression and/or regulation of glutaminase. Both GLS isoen-
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zymes are expressed in BC and GLS, particularly the GAC splice variant, is primarily linked 
to cancer progression and overexpression. Allosteric inhibitors, such as the small molecule 
CB-839, offers a unique opportunity to regulate this important metabolic enzyme. Clinical 
trials in TNBC and haematological malignancies are underway and look promising. However, 
there is still need to understand the role of both GLS and GLS2 in other rapidly proliferating 
BC subtypes including luminal B tumours where inhibition of BC could be a potential thera-
peutic approach, in addition to endocrine therapies that have limited success.  
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Observation on clinical out-
come References
Liver
GLS overexpressed Poor prognosis
[25, 27, 67, 68] GLS2 overexpressed Good prognosis
Colorectal
GLS overexpressed Poor prognosis  [29]
GLS2  yet to be studied
Lung
GLS overexpressed Poor prognosis [31, 58]
GLS2 yet to be studied 
Leukaemia
GLS overexpressed Poor prognosis  [69]
GLS2 yet to be studied
Lymphoma
GLS overexpressed Poor prognosis  [40]
GLS2 yet to be studied
Breast
GLS overexpressed
Poor prognosis in TNBC &   
ER+ (highly proliferative)
[30, 32, 40, 42, 
45]
GLS2 varies among 
subtypes Yet to be studied 
Melanoma
GLS overexpressed Poor prognosis  [70]
GLS2 yet to be studied
Brain
GLS overexpressed Poor prognosis
[24]GLS2 overexpressed Good prognosis
Prostate
GLS overexpressed Poor prognosis  [40, 71]
GLS2  yet to be studied
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Table 2. Clinical trials using GLS inhibitor CB-839  
Source: National Cancer Institute 
Cancer type Clinical trial phase Clinical Trial  number
Renal Cell carcinoma Phase II NCT03428217
Melanoma Phase I/II NCT02771626
NSCLC Phase I/II NCT02771626
Colorectal Phase I/II NCT02861300
Myelodysplastic syndrome Phase I/II NCT02071927
Breast (TNBC) Phase I/II NCT02071862
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Figure 1: Glutamine metabolism in cancer cell. Glutamine is an essential amino acid that 
serves as a carbon and nitrogen source for energy production and nucleotide biosynthesis. 
Amino acid transporters regulate glutamine supply into the intercellular space. Glutamine is 
transported across the plasma membrane mainly by transporters: SLC1A5, SLC7A5. In the 
mitochondrion, either glutaminase, GLS, or GLS2 converts glutamine to glutamate. The latter 
is converted into α-ketoglutarate and enters the TCA cycle for processing. Oncogene c-MYC 
upregulation is responsible for the direct promotion of the expression of glutamine trans-
porters enhancing glutamine entry into the cell and upregulation of GLS. Tumour suppressor 
p53 is a transcriptional target for the GLS2 gene increasing its expression under both stressed 
and non-stressed conditions. GLS inhibitors used to target GLS directly are 6-diazo-5-oxy-L-
norleucine DON, 968, bis-2-(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl) ethyl sulphide 
(BPTES) and CB-839 [1, 58, 66]. 
Figure 2: Structure of the GLS and GLS2 gene. (A) GLS gene is 82kb and contains 19 exons 
on chromosome 2. Alternative splicing of the gene produce KGA and GAC splice variants, 
which share identical N-terminal region and GAM splice variant. KGA is derived from exon 
1-14 and 16-19 while GAC protein is from 1-15 exons but have unique C-termini sequences. 
The central region is the catalytic active site. (B) GLS2 has 18 exons that are 18kb on chro-
mosome 12. Alternative splicing of the gene produce LGA (short transcript) and GAB (long 
transcript) isoforms. The splice variants share a common C-terminus and differ at their N-
termini region. Adapted from [17, 67]. 
Figure 3: GLS and GLS2 mRNA levels in the molecular subtypes of breast cancer and their 
correlation using GeneMiner (a, c, e) and METABRIC (b, d, f) datasets 
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Figure 4: Association of GLS and GLS2 mRNA expression and patient outcome in breast 
cancer using GeneMiner for (a) GLS (b) GLS2 showing low gene (less than the median) ex-
pression is associated with poor patient survival. Combined expression of GLS and GLS2 
mRNA expression and patient outcome in the METABRIC dataset for (c) all breast cancers 
(d) luminal B tumours. 
Figure 5: Immunohistochemical expression of GLS and GLS2 protein in invasive ductal 
breast cancers of no special type. Cytoplasmic GLS showing homogenous and granular im-
munoreactivity, (a) x10 magnification and (b) x20, and GLS2, showing homogenous immun-
oreactivity, (d) x10 and (e) x20, expression. Negative controls for GLS (c, x10) and GLS2 (f, 
x10). 
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